Company intelligence / Profile preview
Avaant Imaging
Lexington, MA, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Avaant Imaging was a biotechnology and molecular imaging company focused on developing novel positron emission tomography (PET) radiotracers to detect and quantify multidrug resistance (MDR) in tumors. The company's lead asset, [18F]AVT-011, is a dual ABCB1 (P-glycoprotein) and ABCG2 substrate radiotracer designed to non-invasively image transporter-mediated chemoresistance. By visualizing the functional status of efflux transporters, Avaant's technology aimed to help clinicians differentiate responders from non-responders before initiating chemotherapy. The company was based in Lexington, Massachusetts, and London, UK, but has since been dissolved.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Avaant Imaging.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avaant Imaging.